Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11857820 | 0.80 | HTR3A (0.43) | HTR3AHRH4 | |
| SCHEMBL1711396 | 0.79 | POLB (0.51) | PIK3R1PIK3CAMTOR | |
| SCHEMBL28267110 | 0.79 | CHI3L1 (0.41) | CDC7ACACBFFAR2LRRK2PIK3CA | |
| SCHEMBL31627720 | 0.79 | CHI3L1 (0.41) | CDC7ACACBFFAR2LRRK2PIK3CA | |
| SCHEMBL28265610 | 0.79 | CHI3L1 (0.41) | CDC7ACACBFFAR2LRRK2PIK3CA | |
| SCHEMBL30595213 | 0.76 | ACACB (0.40) | ACACBLRRK2HTR3AHRH4PIK3R1 | |
| SCHEMBL31718061 | 0.76 | CHI3L1 (0.49) | CDC7FFAR2LRRK2ADORA2AADORA1 | |
| SCHEMBL4516949 | 0.74 | HTR3A (0.47) | HTR3AHRH4 | |
| SCHEMBL22119365 | 0.74 | ACACB (0.43) | ACACBLRRK2 | |
| SCHEMBL20606379 | 0.74 | ACACB (0.46) | CDC7ACACBLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396322-B9 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-09-14 | — | — | EP | disclosed |
| EP-2396322-B1 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-8609666-B2 | 2-morpholino-pyrido[3,2-D]pyrimidines | MERCK SERONO SA (CH) | 2013-12-17 | — | — | US | disclosed |
| EP-2396322-A1 | 2-MORPHOLINO-PYRIDOÝ3,2-D¨PYRIMIDINES | Merck Serono SA (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20110293564-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2011-12-01 | — | — | US | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| EP-2344490-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES ACTIVE ON PI3K | Merck Serono S.A. (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010091996-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010037765-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110293564-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CB | CDC7 1576/4885ACACB 3965/4885FFAR2 1721/4885 |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CG | CDC7 1085/4885ACACB 4168/4885FFAR2 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.